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In immunization against epidemic influenza, one of the most important 
problems is the production of effective resistance to heterologous strains 
of influenza virus.  Recent work has  emphasized  qualitative  differences 
between strains of the virus (1-5).  Other observations have indicated the 
existence of relationships determined by various factors which affect the 
specificity of the immunity, such as the route (3, 6-8)  and the number of 
inoculations (2, 5, 9), the interval after inoculation at which the immunity 
test is done (1, 5), the degree of involvement of the susceptible respiratory 
epithelium (6), the antigenic specificity of the strain (1, 3), and the amount 
of virus used for immunization. 
In the present work an attempt has been made to evaluate quantitatively 
the relationships of several strains of influenza virus as measured by active 
immunity in mice.  In previous quantitative work on heterologous active 
immunity, animals have usually been immunized with a constant amount of 
virus  and  tested  for  immunity with  varying  amounts  inoculated  intra- 
nasally (2, 6).  In the present work the vaccinating dose has been varied 
and the test dose kept constant in order to measure the relative amounts of 
virus given by the  intraperitoneal or by  the intranasal route which are 
required to produce a  comparable immunity to homologous and heterolo- 
gous strains.  An attempt has been made tb  distinguish between factors 
which tend to increase heterologous immunity more than homologous im- 
munity, and  those which merely bring  about  a  quantitative  increase of 
similar degree in the immunity to all strains.  The results indicate that the 
most important factor in cross-immunity is the size of the vaccinating dose. 
* These studies  were made under the auspices, and with the support,  of the Inter- 
national Health Division of The Rockefeller Foundation cooperating with the California 
State Department of Public Health. 
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This is probably dependent  on the  amount  of antigenic  component which 
different strains have in  common. 
A  detailed  study has been made of five strains of influenza virus.  The 
strains  PR8,  Melbourne,  and  Philadelphia  belong  to  the  so  called  "inter- 
mediate"  class  and  have  definite  antigenic  relationships  (1, 3)  while the 
strains W.S.  and swine have been classified as "specific"  (1, 2). 
Materials and Methods 
The material used for immunization was as follows:  (a)  Mouse passage strains PR8, 
W.S., Melbourne, and swine as suspensions  of infected mouse lung in broth.  (b)  Ferret 
passage strains PR8 and Philadelphia as suspensions  of infected ferret lung in broth. 
(c)  The chick embryo tissue culture  strain  of swine  influenza  virus which  had been 
carried by Dr. Francis from infected swine lungs directly to tissue culture. 
The amount of virus used for immunization was measured in  terms of intranasal 
mL.D. as previously described (10), and mice in groups of 8 received 0.5 cc. each  intra- 
peritoneally, or 0.05 cc. intranasally, of serial tenfold dilutions up to and including  dilu- 
tions which contained an amount of virus too small to produce immunity to the homolo- 
gous strain. 
The ferret passage and tissue culture strains were somewhat attenuated for mice (11), 
and they had much more immunizing effect per intranasal ~.L.D. than did the highly 
virulent mouse passage strains.  This made it possible to study the effects on homologous 
and heterologous immunity of intranasal inoculation with various sublethal quantities 
of virus. 
Two weeks after the last immunizing inoculation,  the mice were tested for active 
immunity by intranasal instillation in a volume of 0.05 cc. of between 1 and 10 M.L.D. 
of the homologous and heterologous  strains.  In all of these tests for immunity pre- 
viously titrated  suspensions  of highly virulent  mouse passage strains  of PR8,  W.S., 
Melbourne, Philadelphia,  and swine  were used.  Deaths or survivals with or without 
lung lesions in each group of mice following the test were recorded as percentage scores 
(10) as given by the following expression: 
5a +4b +  3c +  2d +  le 
Percentage score =  ST 
Where a represents the number of mice dead, b, c, d, and e represent the number of 
mice surviving with  + + + +,  + + +,  + +, and  +  lung lesions respectively, and T is 
the total number of mice in the group, including those surviving without lung lesions. 
Measurement  of the Intraperitoneal  Minimal Immunizing Dose for 
Homologous and Heterologous Strains 
Mice were immunized  by one intraperitoneal  injection  of 0.5  cc.  of the 
active mouse passage strains  W.S.,  PR8,  or  Melbourne.  In  a  second ex- 
periment 3 inoculations,  10 days apart, were given in order to compare the 
effect of 1 and 3 injections.  Tests for immunity were done as described in 
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The results are presented in Table I.  The percentage scores of control 
groups of mice which received less than the minimal amount of virus neces- 
sary to immunize against the homologous strain will be seen in the last two 
columns of the table.  When  the scores of groups of mice receiving larger 
amounts  of virus  for immunization  were  less  than  half  the  scores in  the 
corresponding control group,  some active immunity was  considered to  be 
indicated.  When  there  was  no  indication  of  immunity,  the  percentage 
score in the table has been enclosed in parentheses. 
TABLE  I 
Immunity after Intraperitoneat Injection of Active Virus:  Effect of Amount of Virus and 
Number of Injections 
Vaccinated 
with strain 
W.S. 
~c 
c~ 
PR8 
lc 
cc 
Melb. 
lc 
~c 
Tested with 
strain 
W.S. 
PR8 
Melb. 
Swine 
W.S. 
PR8 
Melb. 
Swine 
W.S. 
PR8 
Melb. 
Swine 
1  X 10,000 
M.L.D • 
3 
3 
31 
30 
26 
3 
12 
40 
32 
20 
0 
(78)f 
Percentage scores* of groups of mice immunized  with 
l~0  1 X 1,000 
•  .  .  M.L.D. 
0  27 
12  (65) 
22  (50) 
13  (60) 
25  (53) 
0  12 
0  (43) 
31  (63) 
30  (90) 
lo  (78) 
2  12 
(60)  (72) 
3X10O 
M.L.D. 
12 
(52) 
45 
(40) 
(75) 
8 
(25) 
(42) 
(58) 
(110  ~) 
(83) 
1XIO0 
M.r-.D. 
(75) 
(65) 
000) 
(73) 
(88) 
(56) 
(46) 
(77) 
(100) 
(100) 
(76) 
(78) 
3XlO 
M,L.D. 
(80) 
(98) 
(95) 
(53) 
(78) 
(72) 
(40) 
(47) 
(ioo) 
(89) 
(55) 
(88) 
* In this and succeeding  tables percentage scores enclosed  in parentheses indicate 
absence of immunity.  Expression  1 ×  or 3 ×  before number of ~r.L.D. indicates num- 
ber of immunizing  injections. 
Immunity to the swine strain was obtained with one intraperitoneal dose of 100,000 
M.L.D. of Melbourne. 
In  general,  the  amount  of  active  virus  required  for  immunity  to  the 
heterologous strains was approximately 10 times the minimal immunizing 
dose for the homologous strain.  In mice immunized with the strain Mel- 
bourne and tested with swine influenza virus an exception was noted.  Here 
the ratio of homologous to heterologous minimal immunizing  doses was  1 
to 100.  When mice were immunized by intraperitoneal inoculation of the 
swine  influenza virus  and  tested  with  human  strains,  this  ratio was  still 
larger, as will be shown in a  later section. 
With  3  intraperitoneal  injections,  about  one-third  as  much  total  virus 
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inoculation, but the ratio of homologous to heterologous minimal protective 
doses remained the same.  The results indicated that immunity to both 
homologous and heterologous strains was increased to the same degree by 
repeated immunizing injections. 
With  single  doses  it  was necessary to  inject  10,000 intranasal M.L.D., 
in order to produce some heterologous immunity.  This amount of virus 
will produce lung lesions in some of the mice after injection into the peri- 
toneal cavity, and 100,000 ~r.Lm. given by the same route, although pro- 
ducing solid heterologous immunity in the survivors, usually killed some 
of the mice with complete consolidation of the lungs.  This finding sug- 
gested that  the production of effective heterologous active immunity in 
mice might be dependent on infection of the lung tissue. 
TABLE  II 
Relative Amounts of A ctive and Inactive Influenza Virus Required  for Heterologous 
Immunity after One Intraperitoneal Injection 
Mice immunized with PP,8 mouse lung 
Tested with strain  Active  Inactive 
PR8 
W.S. 
Melb. 
10,000  ]  1,000  100  1,000,000  100~000  10,000  1,000 
units*  units  units  units  umts  units  units 
I  3  12  (56)  0  0  20  (90) 
26  (53)  (88)  25  35  (80)  -- 
12  (43)  (46)  5  10  (90)  -- 
* In this table the term "unit" is used to denote the active or inactive  equivalent of 
one intranasal M.L.D. 
TO investigate this point, experiments were done with formalinized in- 
active  preparations.  The  results  presented  in  Table  II  indicate  that 
heterologous immunity may be induced by intraperitoneal injection of in- 
active virus.  This agrees with the results of Oakley and Warrack (6).  The 
ratio of homologous to heterologous minimal immunizing doses is again 1 
to 10, or the same as with active virus.  However, 10 to 100 times as much 
formalinized inactive virus is  required to produce a  degree of immunity 
comparable to that obtained with active virus (10). 
Homologous and Heterologous Immunity after Intranasal Inoculation of Mice 
with Ferret Passage Strains 
It was shown in a previous study (11) that certain ferret passage strains 
of human influenza virus were capable of producing solid homologous im- 
munity in mice inoculated intranasally with a  very small fraction of an 
~r.L.D.  As may be seen in Table III, solid immunity to heterologous human 
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of mice with  1/100 M.L.D. of the ferret passage  strain  Philadelphia.  Sig- 
nificant immunity to four human strains and partial immunity to the swine 
influenza  virus followed intranasal  instillation  of  1/10,000 M.L.D. 
The  same preparation  after  intraperitoneal  inoculation  gave  some  im- 
munity to the heterologous strains PR8 and Melbourne, but none to W.S. 
or swine.  It appears,  therefore,  that the strain  Philadelphia  has a  rather 
non-specific antigenic  composition and  that  extension of the immunity  to 
other strains is most pronounced after intranasal inoculation. 
In  contrast  to  these  results  with  the  strain  Philadelphia,  intranasal 
inoculation  of mice with  sublethal doses of the ferret passage  strain  PR8 
gave an immunity which was not much less specific than that obtained by 
TABLE  III 
Heterologous Immunity after Intranasal and Intraperitoneal Inoculation with Philadelphia 
Ferret Passage Virus* 
Percentage scores of groups of mice inoculated 
Tested with  Once I.N. with  Once I.P. with 
Phila. 
PR8 
Melb. 
W.S. 
Swine 
1/100 
M.L.D. 
1 
7 
3 
3 
5 
1/1,000  1110,000 
M.L .D.  M  .L.D 
6  16 
3  ll 
--  16 
3  19 
42  47 
I/I00,000 
M.L.D • 
(93) 
(75) 
(95) 
(75) 
(80) 
10 
M  .L.D. 
35 
(75) 
(loo) 
1 
M.L.D. 
40 
20 
42 
(75) 
(ioo) 
1/10 
M.L,D. 
(77) 
(77) 
(90) 
(95) 
(100) 
* With this strain one intranasal ~.L.D. for mice was 0.05 cc. of a 10 per cent suspension 
of ferret lung. 
I.N. = intranasally.  I.P.  = intraperitoneally. 
the intraperitoneal  route of injection.  The results presented in Table IV 
show that mice receiving 1/10,000 of an •.L.D.  developed a  solid immunity 
to the homologous strain  and  to the  strain  Melbourne,  but none  to W.S. 
and  swine.  With  the  exception  of  the  cross-immunity  to  Melbourne,  a 
similar  result  was obtained  by intraperitoneal  inoculation  of  1,000  intra- 
nasal M.L.D. of the mouse passage strain  (Tables I  and II).  The immunity 
was not increased or broadened appreciably by repeated intranasal inocula- 
tion  with  small  amounts  of  virus,  but  a  single  larger  intranasal  dose of 
1/100 ~r.L.D. gave solid immunity to the three heterologous strains. 
Cross-Immunization  with  Swine Influenza  Virus:  Effect  of Route  and 
Number of Injections 
It  has  been  noted  by other  investigators  (7,  8)  that  mice  and  ferrets 
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to human strains.  On the other hand, recovery from infection with one 
human strain does not always confer immunity to another human strain 
either in ferrets  (4)  or in mice  (3).  Because of this discrepancy in  the 
published results, it was considered desirable to reinvestigate, by the appli- 
cation of quantitative methods, the immunity to human strains produced 
by intraperitoneal and intranasal inoculation with swine influenza virus. 
TABLE  IV 
Heterologous Immunity after Intranasal Inoculation with PR8 Ferret Passage Virus 
Percentage scores of groups of mice inoculated with 
Tested with 
PR8 
Melb. 
W.S. 
Swine 
IX  IX  3X  IX 
11100  1/1,000  1/1,000  l/lO,O00 
u.L.D.  ILC.L.D.  M.L.D.  I~r.L.D  . 
5  0  0  5 
0  0  --  10 
5  (55)  25  (73) 
8  (45)  (43)  (77) 
8X  IX  3X 
I/I0,000  11100,000  1/100,000 
M.L.D.  M.L.D.  M.L.D. 
0  (74)  (100) 
(75)  -- 
(50)  (100)  (54) 
(60)  (83)  (62) 
TABLE  V 
Ratio of Homologous to Heterologous Minimal Immunizing Dose in Mice Immunized with 
Swine Influenza  Virus 
Homologous minimal immunizing doses required  for immunity in mice receiving 
Tested with strain 
Swine 
W.S. 
PR8 
Swine M.L.* 
once I.P. 
1 
1,000 
1,000 
Swine M.L. 
thrice I.P. 
1 
1,000 
1,000 
Swine T.C.* 
thrice I.P. 
1 
1,000 
1,000 
Swine T.C. 
once I.N. 
1 
10 
10 
Swine T.C. 
thrice I.N. 
1 
it 
it 
Dilution and number of M.L.D. in homologous minimal  immunizing dose: 
Swine mouse lung I.P.  0.5 cc. of 10  -4 or 1,000 ~.L.D. 
Swine tissue culture I.P.  0.5 cc. of 10  -s or 1 ~.L.D. 
Swine tissue culture I.N. 0.05 cc. of 10  -5 or 1/1,000 ~.L.D. 
* M.L.  =  mouse lung.  T.C.  -- tissue culture. 
t More lesions at each immunizing dilution  than with homologous strain. 
Mice  received  1  and  3  inoculations  of various  amounts of  swine  tissue 
culture and mouse passage strains.  The least amount of virus required for 
immunity against  the homologous swine  strain  in  each  series  of tests was 
taken as the homologous minimal immunizing dose for the route and num- 
ber of inoculations given. 
The results in Table V  are presented in terms of the number of homolo- 
gous (swine)  minimal immunizing doses required for effective heterologous 
immunity  to  the  two  human  strains  W.S.  and  PR8.  When  the  intra- MONROE  D. EATON  AND  HAROLD  E.  PEARSON  641 
peritoneal route of inoculation was used, the ratio in each case was approxi- 
mately  1 to  1,000.  Intranasal inoculation produced a  much less specific 
immunity as indicated by the fact that the minimal amount of swine virus 
required for protection against the human strains was only 10 times that 
required for immunity to the swine strain.  Three intranasal inoculations 
with a dilution of  10  -5 of the swine tissue culture virus protected all mice 
against death when tested with swine and human strains, but lung lesions 
were more frequent and extensive in the mice tested  with the strains PR8 
and W.S. 
DISCUSSION 
The results of the experiments on active immunization of mice by the 
intraperitoneal route indicate that the relationship between certain human 
strains of epidemic influenza virus is determined by common antigens which 
are present in the proportion of 1 part in the heterologous strain to about 
10 parts in the homologous strain.  This follows from the observation that 
effective  heterologous immunity is  obtained  by  injecting  10  times  the 
homologous minimal immunizing dose. 
On the same basis it appears that the amount of human strain antigen 
in the swine influenza virus is approximately one-thousandth of the quan- 
tity of this antigen in the strains PR8, W.S., or Melbourne.  Conversely, 
these human strains  contain one-tenth to  one-hundredth as much swine 
antigen  as  the  swine  strain.  The  quantitative  antigenic  relationships 
between swine and human strains are  therefore not exactly reciprocal, a 
fact originally pointed out by Francis and Shope (12)  as a  result of their 
experiments on the production of neutralizing antibodies. 
The quantitative interpretation just outlined is also in accord with other 
observations.  Repeated intraperitoneal inoculation increases homologous 
and heterologous immunity to the same degree.  The ratio between homol- 
ogous and  heterologous minimal immunizing doses  is  not  altered  when 
inactive virus is used, but enormous amounts of material are required for 
immunity.  The development  of lung lesions does not appear to be essential 
to heterologous immunity.  Taken as a whole, the results are analogous to 
immunization with  serologically and  chemically related  substances  con- 
taining various proportions of antigenic groups.  The degree of immunity 
to  any one antigenic group is proportional to the amount of that group 
injected and is related to the repetition of the stimulus. 
Since the degree of infection-immunity in mice also seemed to be related 
to  the intranasal immunizing dose,  and since multiplication of the virus 
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might be  expected that  the ratio  between homologous and heterologous 
minimal immunizing doses would be  the same as for the intraperitoneal 
route. 
The  experiments on  intranasal  immunization with  the  ferret  passage 
strains PR8 and Philadelphia showed that with minimal doses there was 
relatively more cross-immunity to closely related strains (PR8, Melbourne, 
and Philadelphia)  than after immunization by  the intraperitoneal route. 
However,  the  strain  PR8  exhibited, with  respect  to  W.S.  and  swine,  a 
specificity  which  was  independent of  the  route  of  inoculation.  Strain 
specificity was also apparent after intranasal immunization of mice with 
1/1,000 M.L.D. of swine influenza virus, but a  tenfold increase in the dose 
produced effective cross-immunity to  human strains.  By  the intraperi- 
toneal route  1,000  homologous minimal immunizing doses were  required 
for heterologous immunity.  In this connection it is of some interest to 
note that the antigenic differences between the two human strains PR8 and 
W.S., as judged by quantitative intranasal immunity tests, were somewhat 
more pronounced than the differences between swine and human strains 
(Tables IV and V). 
The broader immunity obtained by intranasal inoculation, as compared 
with intraperitoneal immunization, appeared  to  be  due  to  factors other 
than  the  antigenic composition of  the virus.  The possibility of a  non- 
specific local resistance following infection must be considered, but if this 
is the correct explanation, it is obvious from the results just discussed that 
some strains increase  this local resistance while others have  a  negligible 
effect. 
The experiments on immunization of mice raise certain questions as to 
the quantity of virus necessary for protection of human beings.  On the 
basis of body weight, the amount of tissue containing active or inactive 
virus which is required to produce effective heterologous immunityin mice 
by intraperitoneal inoculation is at least  1,000  times any dosage yet at- 
tempted in man.  On the other hand, heterologous immunity in mice was 
obtained by intranasal inoculation with relatively minute doses of partially 
attenuated virus.  Similar observations by Burnet (3) have indicated the 
possibilities of intranasal inoculation, and Francis  (13)  has recently pub- 
lished observations on intranasal  inoculation of  human beings with  the 
tissue culture strain PR8. 
SUMMARY 
When mice are immunized by one intraperitoneal inoculation with active 
or inactive influenza virus (strain PR8, W.S., and Melbourne) the quantity MONROE D.  EATON AND  HAROLD E.  PEARSON  643 
required for protection against heterologous strains is about  10 times the 
homologous minimal immunizing dose.  Three injections increase the im- 
munity to all strains, but the ratio between the homologous and heterologous 
minimal immunizing dose is not altered. 
Swine influenza virus given intraperitoneally fails to immunize against 
human  strains  unless  the  quantity  injected is  1,000 times  the  minimal 
amount required for homologous immunity. 
Intranasal immunization of mice with 1/100 M.L.D. of attenuated ferret 
passage strains PR8 and Philadelphia, or the tissue culture strain of swine 
influenza, gives a  solid resistance to infection with heterologous strains. 
When smaller amounts of virus  are given intranasally,  strain  specificity 
becomes more apparent,  and with minimal doses the immunity may be 
effective only against the homologous and closely related strains. 
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